Previous 10 | Next 10 |
2023-08-04 16:30:18 ET Galapagos NV (GLPG) Q2 2023 Results Conference Call August 04, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commer...
2023-08-03 17:32:46 ET Galapagos press release ( NASDAQ: GLPG ): 1H GAAP EPS of €0.43. Revenue of €328.8M (+20.0% Y/Y). For further details see: Galapagos GAAP EPS of €0.43, revenue of €328.8M
Half-year 2023 key financials Group revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023 Full year 2023 net sales guidance for Jyseleca® lowered to ...
2023-06-15 16:13:31 ET Biotechnology company Galapagos ( NASDAQ: GLPG ) said on Thursday that Thad Huston has been appointed CFO and COO, effective July 1. Huston currently serves as head of finance and corporate operations at Kite, a Gilead company. Source:...
Mechelen, Belgium; 15 June 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of T had Huston as Chief Financial Officer (C F O) and Chief Operating ...
Mechelen, Belgium; 12 June 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 12 June 2023 , the Board of Directors co-opted Dr. Susanne S chaffert as no n-executive indepe...
All 7 out of 7 eligible patients with relapsed/refractory c hronic l ymphocytic l eukemia ( rrCLL ) , with or without Richter’s T ransformation (RT) , responded to treatment (Objective Response Rate of 100%) 1 GLPG5201...
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and, if approved, has the potential to be the first selective oral TYK2 inhibitor in de...
9 poster presentations and 3 abstracts publications reinforce Galapagos' commitment to immunology and the rheumatoid arthritis (RA) patient and healthcare professional community New analyses will be presented from long-term extension studies providing insights into filgotinib's ...
2023-05-15 18:15:06 ET Hedge fund manager David Einhorn's Greenlight Capital picked up new stakes in Black Knight ( BKI ), First Citizens BancShares ( FCNCA ) and New York Community Bancorp ( NYSE: NYCB ) during Q1, its latest 13F filing showed. The company e...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...